Data gathered: March 6
AI Stock Analysis - Conduit Pharmaceuticals (CDT)
Analysis generated January 24, 2025. Powered by Chat GPT.
Conduit Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of treatments for various diseases. The company’s mission is to innovate and bring to market transformative therapies. Over the years, Conduit Pharmaceuticals has built a reputation for being at the forefront of medical technology and pharmaceutical advancements.
Stock Alerts - Conduit Pharmaceuticals (CDT)
 |
Conduit Pharmaceuticals | March 5 Price is down by -8.4% in the last 24h. |
|
Conduit Pharmaceuticals | March 4 Price is down by -6% in the last 24h. |
|
Conduit Pharmaceuticals | March 3 Price is down by -5.8% in the last 24h. |
|
Conduit Pharmaceuticals | February 28 Price is up by 6.7% in the last 24h. |
Alternative Data for Conduit Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 47 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Google Trends | 5 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 48 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,728 | Sign up | Sign up | Sign up |
| Twitter Mentions | 169 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 3 | Sign up | Sign up | Sign up |
About Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
| Price | $1.07 |
| Target Price | Sign up |
| Volume | 1,580,000 |
| Market Cap | $5.3M |
| Year Range | $1.07 - $106 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest UpdateFebruary 28 - ETF Daily News |
|
Head to Head Review: DiaMedica Therapeutics (NASDAQ:DMAC) versus Conduit Pharmaceuticals (NASDAQ:CDT)February 16 - ETF Daily News |
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus ModelFebruary 13 - GlobeNewswire |
|
Conduit Pharmaceuticals Inc. (CDT) Advances AI-Driven Drug Development to Phase IIFebruary 8 - Yahoo Entertainment |
|
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial IntelligenceJanuary 28 - GlobeNewswire |
|
 |
Conduit Pharmaceuticals Inc trading halted, news pendingJanuary 24 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 50,000 | 2.7M | -2.7M | -6.5M | -6.1M | -0.074 |
| Q2 '24 | 604M | 3.1M | -3.1M | -5.4M | -5.3M | -0.073 |
| Q1 '24 | 536M | 2.8M | -2.8M | -3.6M | -3M | -0.048 |
| Q4 '23 | 0 | 810,000 | -1.1M | 280,000 | 1.9M | -0.015 |
| Q3 '23 | 150,000 | 1.1M | -920,000 | 2.6M | 2M | -0.003 |
Insider Transactions View All
| Nirland Ltd filed to sell 6,092,000 shares at $0.1. October 7 '24 |
| Nirland Ltd filed to sell 7,031,009 shares at $0.1. October 7 '24 |
| Nirland Ltd filed to sell 8,400,000 shares at $0.1. October 7 '24 |
| Nirland Ltd filed to sell 9,900,000 shares at $0.1. October 2 '24 |
| Nirland Ltd filed to sell 10,233,177 shares at $0.1. October 2 '24 |
Similar companies
Read more about Conduit Pharmaceuticals (CDT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Conduit Pharmaceuticals?
The Market Cap of Conduit Pharmaceuticals is $5.3M.
What is the current stock price of Conduit Pharmaceuticals?
Currently, the price of one share of Conduit Pharmaceuticals stock is $1.07.
How can I analyze the CDT stock price chart for investment decisions?
The CDT stock price chart above provides a comprehensive visual representation of Conduit Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Conduit Pharmaceuticals shares. Our platform offers an up-to-date CDT stock price chart, along with technical data analysis and alternative data insights.
Does CDT offer dividends to its shareholders?
As of our latest update, Conduit Pharmaceuticals (CDT) does not offer dividends to its shareholders. Investors interested in Conduit Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Conduit Pharmaceuticals?
Some of the similar stocks of Conduit Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.